Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. METHODS: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. CONCLUSIONS: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“R adiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer ( 1 , 2 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [2]
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“These are particularly substantial in the post-ARPI space, as pivotal trials of many current treatments were performed in patients who had not received a prior ARPI [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Additionally, pivotal trials of current treatments utilized conventional imaging to determine metastatic disease [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Best standard non- | ALSYMPCA Castration refractory | OS | | | 11.3 months 3.6 months | 0.70 (0.55-0.88) Improved | 5 | [68]”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“Asthenia 35 (6) 5 (1) 0 0 18 (6) 4 (1) 0 0”
InfluentialSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Research works printed but not linked: 4
- Lewington VJ, 2005, J Nucl Med, 46, 38S
- Henriksen G, 2002, Cancer Res, 62, 3120
- Henriksen G, 2003, J Nucl Med, 44, 252
- Liepe K, 2009, Curr Opin Investig Drugs, 10, 1346
Cited by
Items 201–300 of 1,005
Taïeb, D., Jha, A., Treglia, G., & Pacák, K. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0165 · Cited by 137
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
Xu, Y., Song, G., Xie, S., Jiang, W., Chen, X., Chu, M., Hu, X., & Wang, Z. P. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.029 · Cited by 131
Past, Current, and Future of Immunotherapies for Prostate Cancer
Boettcher, A. N., Usman, A., Morgans, A., VanderWeele, D. J., Sosman, J. A., & Wu, J. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00884 · Cited by 121
Chittenden, S. J., Hindorf, C., Parker, C. C., Lewington, V. J., Pratt, B. E., Johnson, B., & Flux, G. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.157123 · Cited by 118
Self-citationMoreira, D. M., Howard, L. E., Sourbeer, K. N., Amarasekara, H. S., Chow, L. C., Cockrell, D. C., Pratson, C. L., Hanyok, B. T., Aronson, W. J., Kane, C. J., et al. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.08.018 · Cited by 118
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
Chi, K. N., Hotte, S. J., Joshua, A. M., North, S. A., Wyatt, A. W., Collins, L. L., & Fred Saad, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv267 · Cited by 123
Consensus on molecular imaging and theranostics in prostate cancer
Fanti, S., Minozzi, S., Antoch, G., Banks, I., Briganti, A., Carrió, I., Chiti, A., Clarke, N. W., Eiber, M., Bono, J. S. D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30604-1 · Cited by 124
Self-citationCastration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
Le, T. K., Duong, Q. H., Baylot, V., Fargette, C., Baboudjian, M., Colleaux, L., Taïeb, D., & Rocchi, P. (2023) · Cancers · doi:10.3390/cancers15205047 · Cited by 147
“Radium-223 has been demonstrated to prolong OS in symptomatic patients who have suffered from multiple-bone-metastatic CRPC, without visceral or nodal involvement [111].”
BackgroundHagemann, U. B., Ellingsen, C., Schuhmacher, J., Kristian, A., Mobergslien, A., Cruciani, V., Wickstroem, K., Schatz, C. A., Kneip, C., Golfier, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3476 · Cited by 117
“Following the worldwide marketing authorization of the first-in-class TAT Xofigo (radium223dichloride) for the treatment ofmCRPC (2), there has been an increased interest in new applications of TAT.”
InfluentialSpencer, K. L., Parrish, R., Barton, R., & Henry, A. M. (2018) · BMJ · doi:10.1136/bmj.k821 · Cited by 128
Theranostic radiopharmaceuticals: established agents in current use
Ballinger, J. R. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170969 · Cited by 131
Yadav, M. P., Ballal, S., Bal, C., Sahoo, R. K., Damle, N. A., Tripathi, M., & Seth, A. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002833 · Cited by 122
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, P. I., & Antonarakis, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1464388 · Cited by 121
“Even after several advances in the last decade, with the approval of numerous medications which demonstrated overall survival (OS) improvements (docetaxel [7], sipuleucel-T [8], cabazitaxel [9] abiraterone [10], enzalutamide [11], and radium-223 [12]), median OS still averages 2–3 years after the tumor becomes resista…”
BackgroundAuger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen
Kiess, A. P., Minn, I., Chen, Y., Hobbs, R., Sgouros, G., Mease, R. C., Pullambhatla, M., Shen, C. J., Foss, C. A., & Pomper, M. G. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.155929 · Cited by 111
α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 2
Poty, S., Francesconi, L. C., McDevitt, M. R., Morris, M. J., & Lewis, J. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.204651 · Cited by 114
“ALSYMPCA, a phase III randomized double-blind placebo-controlled trial, was performed to evaluate the efficacy and safety of 223Ra-dichloride (50 kBq/kg every 4 wk for a total of 6 cycles) versus placebo plus the standard of care in symptomatic CRPC patients (31).”
MethodWestdorp, H., Creemers, J. H. A., van Oort, I. M., Schreibelt, G., Gorris, M. A. J., Mehra, N., Simons, M., de Goede, A. L., van Rossum, M. M., Croockewit, A. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0787-6 · Cited by 112
Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
Rijnders, M., de Wit, R., Boormans, J. L., Lolkema, M. P., & van der Veldt, A. A. M. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.012 · Cited by 120
Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
Amaral, T. M. S., Macedo, D., Fernandes, I., & Costa, L. (2012) · Prostate Cancer · doi:10.1155/2012/327253 · Cited by 133
Fendler, W. P., Kratochwil, C., Ahmadzadehfar, H., Rahbar, K., Baum, R. P., Schmidt, M. C., Pfestroff, A., Lützen, U., Prasad, V., Heinzel, A., et al. (2016) · Nuklearmedizin - NuclearMedicine · doi:10.1055/s-0037-1616480 · Cited by 120
Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment
Mansinho, A., Macedo, D., Fernandes, I., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-99286-0_7 · Cited by 120
Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer de la prostate
Rozet, F., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mongiat-Artus, P., Ouzzane, A., Ploussard, G., Azria, D., et al. (2016) · The French Journal of Urology · doi:10.1016/s1166-7087(16)30705-9 · Cited by 123
Theranostic approaches in nuclear medicine: current status and future prospects
Filippi, L., Chiaravalloti, A., Schillaci, O., Cianni, R., & Bagni, O. (2020) · Expert Review of Medical Devices · doi:10.1080/17434440.2020.1741348 · Cited by 117
Parker, C. C., Coleman, R. E., Sartor, O. A., Vogelzang, N. J., Bottomley, D., Heinrich, D. A., Helle, S. I., O’Sullivan, J. M., Fosså, S. D., Chodacki, A., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.021 · Cited by 115
“Overall in this updated analysis of the original ALSYMPCA study publication [9], 564/600 (94%) radium-223 and 292/301 (97%) placebo patients had one or more TEAEs during the treatment period up to 12 wk following the last injection (Table 2).”
BackgroundMethodSelf-citationSternberg, C., Armstrong, A., Pili, R., Ng, S., Huddart, R., Agarwal, N., Khvorostenko, D., Lyulko, O., Brize, A., Vogelzang, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9697 · Cited by 105
Self-citationGenetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
Lozano, R., Castro, E., Aragón, I. M., Cendón, Y., Cattrini, C., Lopez-Casas, P. P., & Olmos, D. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01114-x · Cited by 118
Recent trends in the management of advanced prostate cancer
Ritch, C. R., & Cookson, M. S. (2018) · F1000Research · doi:10.12688/f1000research.15382.1 · Cited by 111
Halabi, S., Armstrong, A. J., Sartor, O. A., Bono, J. S. D., Kaplan, E. B., Lin, C., Solomon, N. C., & Small, E. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3201 · Cited by 113
Self-citationRadionuclides for Targeted Therapy: Physical Properties
Stokke, C., Kvassheim, M., & Blakkisrud, J. (2022) · Molecules · doi:10.3390/molecules27175429 · Cited by 131
“This is due to [(223)Ra]RaCl2 (Xofigo) treatment for castration-resistant prostate cancer, where the bone-seeking properties of radium as a calcium-analogue are exploited [22].”
BackgroundLeibowitz‐Amit, R., Templeton, A. J., Omlin, A. G., Pezaro, C. J., Atenafu, E. G., Keizman, D., Vera-Badillo, F., Seah, J.-A., Attard, G., Knox, J. J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt581 · Cited by 113
Heidenreich, A., Sergio Bracarda, A., Mason, M. D., Özen, H., Sengeløv, L., van Oort, I. M., Papandreou, C. N., Fosså, S. D., Hitier, S., & Climent, M. Á. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.006 · Cited by 108
Self-citationHager, S., Ackermann, C. J., Joerger, M., Gillessen, S., & Omlin, A. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw156 · Cited by 108
The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC)
Fred Saad, C., Chi, K., Finelli, A., Hotte, S. J., Izawa, J. I., Kapoor, A., Kassouf, W., Loblaw, A., North, S. A., Rendon, R., et al. (2015) · Canadian Urological Association Journal · doi:10.5489/cuaj.2526 · Cited by 113
Abou, D. S., Ulmert, D., Doucet, M., Hobbs, R. F., Riddle, R. C., & Thorek, D. L. J. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv380 · Cited by 107
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment
Jadvar, H. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.17.18264 · Cited by 112
“The Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) clinical trial was a randomized, double-blind, multinational investigation of 223Ra dichloride versus placebo (saline) in men with CRPC who had symptomatic bone metastases and no visceral metastases (metastatic lymph nodes up to 3 cm in short axis were allowed)…”
MethodCombined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
Choi, J., Beaino, W., Fecek, R. J., Fabian, K. P., Laymon, C. M., Kurland, B. F., Storkus, W. J., & Anderson, C. J. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209510 · Cited by 103
Metastatic prostate cancer and the bone: significance and therapeutic options
Gartrell, B. A., Coleman, R., Efstathiou, E., Fizazi, K., Logothetis, C. J., Smith, M. R., Sonpavde, G., Sartor, O., & Saad, F. (2015) · European Urology · doi:10.1016/j.eururo.2015.06.039 · Cited by 101
Self-citationCurrent therapeutic options in metastatic castration-resistant prostate cancer
Ingrosso, G., Detti, B., Scartoni, D., Lancia, A., Giacomelli, I., Baki, M., Carta, G. A., Livi, L., & Santoni, R. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.10.001 · Cited by 110
Barbosa, F. D. G., Queiroz, M. A., Nunes, R. F., Viana, P. C. C., Marin, J. F. G., Cerri, G. G., & Buchpiguel, C. A. (2019) · Radiographics · doi:10.1148/rg.2019180079 · Cited by 100
Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
Jang, A., Kendi, A. T., & Sartor, O. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231157632 · Cited by 104
Self-citationMorgan, K. A., Rudd, S. E., Noor, A., & Donnelly, P. S. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00456 · Cited by 105
Spectroscopic and computational investigation of actinium coordination chemistry
Ferrier, M. G., Batista, E. R., Berg, J. M., Birnbaum, E. R., Cross, J. N., Engle, J. W., Pierre, H. S. L., Kozimor, S. A., Lezama-Pacheco, J. S., Stein, B. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms12312 · Cited by 99
Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain
von Moos, R., Costa, L., Ripamonti, C. I., Niepel, D., & Santini, D. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.021 · Cited by 118
Radium 223 dichloride for prostate cancer treatment
Deshayes, E., Roumiguié, M., Thibault, C., Beuzeboc, P., Cachin, F., Hennequin, C., Huglo, D. G., Rozet, F., Kassab‐Chahmi, D., Rébillard, X., et al. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s122417 · Cited by 108
“symptomatic bone metastases.(29) This study included only patients with disease progression after or during docetaxel treatment (the only available agent at the time of the trial that showed some OS benefit in mCRPC), or unfit to receive chemotherapy (43% of the enrolled men).”
BackgroundAlcorn, S. R., Artal, A., Bradfield, L., Brennan, M., Dennis, K. E. B., Diaz, D. A., Doung, Y.-C., Elmore, S. N. C., Hertan, L. M., Johnstone, C., et al. (2024) · Practical Radiation Oncology · doi:10.1016/j.prro.2024.04.018 · Cited by 123
Velho, P. I., Qazi, F., Hassan, S., Carducci, M. A., Denmeade, S. R., Markowski, M. C., Thorek, D. L. J., DeWeese, T. L., Song, D. Y., Tran, P. T., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.040 · Cited by 100
“8 mo until ALP progression for radium-223 and placebo, respectively) [16], although direct comparisons cannot be made.”
Navalkissoor, S., & Grossman, A. (2019) · Neuroendocrinology · doi:10.1159/000494760 · Cited by 98
Targeted Alpha Therapy: Current Clinical Applications
Liberal, F. D. C. G., O’Sullivan, J. M., McMahon, S. J., & Prise, K. M. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3576 · Cited by 121
Self-citationDeegen, P., Thomas, O., Nolan-Stevaux, O., Li, S., Wahl, J., Bogner, P., Aeffner, F., Friedrich, M., Liao, M. Z., Matthes, K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3725 · Cited by 96
Mechanisms, Diagnosis and Treatment of Bone Metastases
Ban, J., Fock, V., Aryee, D. N. T., & Kovar, H. (2021) · Cells · doi:10.3390/cells10112944 · Cited by 124
“Radiopharmaceuticals incorporate into new bone and emit particles (alpha and beta) to kill nearby cancer cells [218,219].”
BackgroundAdvances in the management of castration resistant prostate cancer
Ritch, C. R., & Cookson, M. S. (2016) · BMJ · doi:10.1136/bmj.i4405 · Cited by 109
Immune Checkpoint Inhibitors in Prostate Cancer
Venkatachalam, S., McFarland, T. R., Agarwal, N., & Swami, U. (2021) · Cancers · doi:10.3390/cancers13092187 · Cited by 106
“Radium-223 dichloride (radium-223) is an alpha-particle emitting radiotherapeutic agent that accumulates preferentially in areas of high bone turnover such as bone metastasis and has shown to improve OS in mCRPC patients with bone metastasis [68].”
BackgroundKhreish, F., Ghazal, Z., Marlowe, R. J., Rosar, F., Sabet, A., Maus, S., Linxweiler, J., Bartholomä, M. D., & Ezziddin, S. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05525-7 · Cited by 113
Coleman, R. E., Aksnes, A.-K., Naume, B., Garcia, C. A., Jérusalem, G., Piccart, M. J., Vobecky, N., Thuresson, M., & Flamen, P. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2939-1 · Cited by 97
Self-citationAbou, D. S., Thiele, N. A., Gutsche, N. T., Villmer, A., Zhang, H., Woods, J. J., Baidoo, K. E., Escorcia, F. E., Wilson, J. J., & Thorek, D. L. J. (2021) · Chemical Science · doi:10.1039/d0sc06867e · Cited by 100
Shibata, H., Kato, S., Sekine, I., Abe, K., Araki, N., Iguchi, H., Izumi, T., Inaba, Y., Osaka, I., Kato, S., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000037 · Cited by 97
Vogelzang, N. J., Coleman, R. E., Michalski, J. M., Nilsson, S. F., O’Sullivan, J. M., Parker, C. C., Widmark, A., Thuresson, M., Xu, L., Germino, J., et al. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.07.027 · Cited by 103
“1 (9-16) Neutrophils (absolute), 10(9)/L 4.”
InfluentialSelf-citationNormal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95
“Radiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer (1,2).”
BackgroundNovel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
de Leeuw, R., Berman-Booty, L. D., Schiewer, M. J., Ciment, S. J., Den, R. B., Dicker, A. P., Kelly, W. K., Trabulsi, E. J., Lallas, C. D., Gomella, L. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1358 · Cited by 101
Pandit-Taskar, N. D., Larson, S. M., & Carrasquillo, J. A. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112482 · Cited by 97
Harnessing progress in radiotherapy for global cancer control
Jaffray, D. A., Knaul, F. M., Baumann, M. A., & Gospodarowicz, M. K. (2023) · Nature Cancer · doi:10.1038/s43018-023-00619-7 · Cited by 107
“…randomized trial of radium-223 in castration-resistant prostate cancer with bone metastasis and without visceral metastasis showed that addition of six doses of 50 Bq of radium-223 to standard treatment prolonged median overall survival from 11.3 to 14.9 months and relieved symptoms 89 .”
BackgroundInfluentialBeer, T. M., Hotte, S. J., Fred Saad, C., Alekseev, B. Y., Matveev, V. B., Fléchon, A., Gravis, G., Joly, F., Chi, K. N., Malik, Z., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30605-8 · Cited by 105
Ohshima, Y., Sudo, H., Watanabe, S., Nagatsu, K., Tsuji, A. B., Sakashita, T., Ito, Y. M., Yoshinaga, K., Higashi, T., & Ishioka, N. S. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3919-6 · Cited by 101
“On the other hand, because of the short range of α-particles (<100 μm) radiation-induced side effects are minimized in the clinical setting [37].”
BackgroundChien, M., Lin, Y.-W., Wen, Y., Yang, Y.-C., Hsiao, M., Chang, J.-L., Huang, H.-C., & Lee, W.-J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1247-3 · Cited by 97
Current perspectives on bone metastases in castrate-resistant prostate cancer
Logothetis, C. J., Morris, M. J., Den, R. B., & Coleman, R. E. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9719-4 · Cited by 91
“Results of the ALSYMPCA (ALpharadin in SYMPtomatic Prostate Cancer; NCT00699751) trial showed that Ra-223 improved OS in patients with CRPC, irrespective of previous treatment with docetaxel chemotherapy [15, 41].”
BackgroundSelf-citationRecent Advances in Radiometals for Combined Imaging and Therapy in Cancer
Álvarez, N. H., Bauer, D., Hernández‐Gil, J., & Lewis, J. S. (2021) · ChemMedChem · doi:10.1002/cmdc.202100135 · Cited by 104
Rationale for Modernising Imaging in Advanced Prostate Cancer
Padhani, A. R., Lecouvet, F. E., Tunariu, N., Koh, D., Keyzer, F. D., Collins, D. J., Sala, E., Fanti, S., Vargas, H. A., Petralia, G., et al. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.06.018 · Cited by 98
“nodal metastases also precludes the use of some treatments such as the alpha particle emitter radium 223 [36].”
Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer
Smolle, M. A., Bauernhofer, T., Pummer, K., Călin, G. A., & Pichler, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020473 · Cited by 97
“As a consequence, taxane-based chemotherapy may be initiated or a bone-targeting agent (radium 231) might be administered [18].”
BackgroundBanerjee, S. R., Minn, I., Kumar, V., Josefsson, A., Lisok, A., Brummet, M. E., Chen, J., Kiess, A. P., Baidoo, K. E., Brayton, C. F., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229393 · Cited by 101
“A proof-of-concept therapy study with a single administration of 212Pb-L2 demonstrated dose-dependent inhibition of tumor growth in the PSMA(1) flank tumor model.”
BackgroundMethodInfluentialDosimetry in Radiopharmaceutical Therapy
O’Donoghue, J. A., ZANZONICO, P. B., Humm, J. L., & Kesner, A. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262305 · Cited by 118
“Recent approvals of new therapeutic radiopharmaceuticals were based on the results of randomized controlled clinical trials (3,12,26).”
BackgroundDanila, D. C., Szmulewitz, R. Z., Vaishampayan, U., Higano, C. S., Baron, A. D., Gilbert, H. N., Brunstein, F., Milojic-Blair, M., Wang, B., Kabbarah, O., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00646 · Cited by 90
“Peripheral neuropathy* 1 (7) — 2 (29) 1 (14) 26 (67) 2 (5) 10 (63) — 39 (51) 3 (4)”
Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging
Duan, H., Iagaru, A. H., & Aparici, C. M. (2021) · Nanotheranostics · doi:10.7150/ntno.64141 · Cited by 110
“Quality of life has been significantly improved in the treatment group [99].”
BackgroundActinium-225 targeted alpha particle therapy for prostate cancer
Bidkar, A. P., Zerefa, L., Yadav, S., VanBrocklin, H. F., & Flavell, R. R. (2024) · Theranostics · doi:10.7150/thno.96403 · Cited by 104
“Radium-223's remarkable ability to selectively target bone metastases has led to improved overall survival rates and a significant delay in the development of symptomatic skeletal lesions [135].”
BackgroundMcNeel, D. G., Eickhoff, J. C., Wargowski, E., Zahm, C. D., Staab, M. J., Straus, J., & Liu, G. (2018) · Oncotarget · doi:10.18632/oncotarget.25387 · Cited by 90
“These agents include docetaxel [2, 3], cabazitaxel [4], sipuleucel-T [5], abiraterone [6], enzalutamide [7], and radium-223 [8].”
BackgroundCellular rewiring in lethal prostate cancer: the architect of drug resistance
Carceles‐Cordon, M., Kelly, W. K., Gomella, L. G., Knudsen, K. E., Rodríguez-Bravo, V., & Domenech, J. M. D. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0298-8 · Cited by 101
Saeed, K., Rahkama, V., Eldfors, S., Bychkov, D., Mpindi, J. P., Yadav, B., Paavolainen, L., Aittokallio, T., Heckman, C., Wennerberg, K., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.04.019 · Cited by 89
Epigenetic modulators as therapeutic targets in prostate cancer
Graça, I. C. R., Pereira-Silva, E., Henrique, R., Packham, G., Crabb, S. J., & Jerónimo, C. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0264-8 · Cited by 102
AR function in promoting metastatic prostate cancer
Augello, M. A., Den, R. B., & Knudsen, K. E. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9471-3 · Cited by 88
Rozet, F., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mongiat-Artus, P., Ploussard, G., Mathiéu, R., Brureau, L., et al. (2018) · The French Journal of Urology · doi:10.1016/j.purol.2019.01.007 · Cited by 102
Juzeniene, A., Stenberg, V. Y., Bruland, Ø. S., & Larsen, R. H. (2021) · Cancers · doi:10.3390/cancers13040779 · Cited by 99
Self-citationJames, N. D., Pirrie, S. J., Pope, A., Barton, D., Andronis, L., Goranitis, I., Collins, S. I., Daunton, A., McLaren, D. B., O’Sullivan, J. M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5570 · Cited by 93
Self-citationAhmadzadehfar, H., Schlolaut, S., Fimmers, R., Yordanova, A., Hirzebruch, S., Schlenkhoff, C., Gaertner, F. C., Awang, Z. H., Hauser, S., & Essler, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21600 · Cited by 86
“In concordance with other studies [13, 25], we found that an ALP cut-off level of 220 U/l was significant in the univariate analysis.”
ResultBone Metastasis Pain, from the Bench to the Bedside
Aielli, F., Ponzetti, M., & Rucci, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020280 · Cited by 99
Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
Imamura, Y., & Sadar, M. D. (2016) · International Journal of Urology · doi:10.1111/iju.13137 · Cited by 86
ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals
Yonekura, Y., Mattsson, S., Flux, G., Bolch, W. E., Dauer, L. T., Fisher, D. R., Laßmann, M., Palm, S., Hosono, M., Doruff, M., et al. (2019) · Annals of the ICRP · doi:10.1177/0146645319838665 · Cited by 107
The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer
Nair, S. S., Weil, R., Dovey, Z. S., Davis, A., & Tewari, A. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.10.005 · Cited by 98
Rathkopf, D. E., Antonarakis, E. S., Shore, N. D., Tutrone, R. F., Jr., Alumkal, J. J., Ryan, C. J., Saleh, M. N., Hauke, R. J., Bandekar, R. R., Maneval, E. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2509 · Cited by 94
“7 7 (28) 14 (67) 8–10 18 (72) 6 (29) Missing 0 1 (5)”
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
Handkiewicz-Junak, D., Poeppel, T. D., Bodei, L., Aktolun, C., Ezziddin, S., Giammarile, F., Bolton, R. C. D., & Gabriel, M. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3947-x · Cited by 86
“Not only has radionuclide therapy with alpha-emitting radionuclides (radium-223) been used to treat bone metastasis-related pain, but it has also recently been demonstrated to prolong patient survival [5].”
BackgroundClinical Advances and Perspectives in Targeted Radionuclide Therapy
Lepareur, N., Ramée, B., Mougin‐Degraef, M., & Bourgeois, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061733 · Cited by 100
“There have been impressive results with some therapeutic radiopharmaceuticals or radioactive constructs not actively targeted at a specific site, such as the aforementioned radioiodine, [223Ra]radium dichloride, for the management of painful bone metastases in mCRPC patients or radioembolization of liver cancers [1,10…”
BackgroundDeek, M. P., Taparra, K., Phillips, R., Velho, P. I., Gao, R. W., Deville, C., Song, D. Y., Greco, S., Carducci, M., Eisenberger, M., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2020.05.004 · Cited by 96
The evolution of chemotherapy for the treatment of prostate cancer
Quinn, D. I., Sandler, H. M., Horvath, L. G., Goldkorn, A., & Eastham, J. A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx348 · Cited by 98
Is There a Role for Immunotherapy in Prostate Cancer?
Rizzo, A., Mollica, V., Cimadamore, A., Santoni, M., Scarpelli, M., Giunchi, F., Cheng, L., López-Beltrán, A., Fiorentino, M., Montironi, R., et al. (2020) · Cells · doi:10.3390/cells9092051 · Cited by 92
Petrylak, D. P., Kantoff, P., Vogelzang, N. J., Mega, A., Fleming, M. T., Stephenson, J. J., Frank, R., Shore, N. D., Dreicer, R., McClay, E. F., et al. (2019) · The Prostate · doi:10.1002/pros.23765 · Cited by 84
Self-citation232 Th-Spallation-Produced 225 Ac with Reduced 227 Ac Content
Robertson, A. K. H., McNeil, B. L., Yang, H., Gendron, D., Perron, R., Radchenko, V., Zeisler, S., Causey, P. W., & Schaffer, P. C. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c01081 · Cited by 92
Rathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D. W., Lakhani, N. J., Hawley, J. E., Srinivas, S., Aparicio, A. M., Narayan, V., Runcie, K. D., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.005 · Cited by 97
Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
Bumbaca, B., & Li, W. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.007 · Cited by 90
Crona, D. J., Milowsky, M., & Whang, Y. E. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.256 · Cited by 87
Yu, E. Y., Kolinsky, M. P., Berry, W. R., Retz, M. M., Mourey, L., Piulats, J. M., Appleman, L. J., Romano, E., Gravis, G., Gurney, H., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.02.023 · Cited by 86
Vaccines as treatments for prostate cancer
Rastogi, I., Muralidhar, A., & McNeel, D. G. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00739-w · Cited by 91
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)
ICECaP Working Group (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv261 · Cited by 89
Osteoblastic Factors in Prostate Cancer Bone Metastasis
Lin, S.-C., Yu‐Lee, L., & Lin, S.-H. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0480-6 · Cited by 93
Metadata
- Authors
- Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Coleman, R., Vogelzang, N. J., O'Bryan-Tear, C. G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, Ø. S., & Sartor, O.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 213-223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141454098
- Cited by
- 3,408
- References
- 36
- Citations by year
- 2026: 162 · 2025: 213 · 2024: 230 · 2023: 252 · 2022: 253 · 2021: 307 · 2020: 274 · 2019: 268 · 2018: 321 · 2017: 279 · 2016: 288 · 2015: 253 · 2014: 250 · 2013: 50
- FWCI
- 228.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- radium-223 dichloride, alpha-emitting radiopharmaceuticals, castration-resistant prostate cancer, bone metastasis, overall survival, skeletal-related events, docetaxel, myelosuppression, treatment safety, ALSYMPCA trial, interim analysis
- MeSH terms
- Aged, Aged, 80 and over, Bone Neoplasms, Double-Blind Method, Humans, Isotopes, Male, Middle Aged, Prostatic Neoplasms, Radium, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.